Treatment with biological products for chronic rhinosinusitis with nasal polyp
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Seung Cheol | - |
dc.contributor.author | Cha, Hyunkyung | - |
dc.contributor.author | Kim, Dong-Young | - |
dc.date.accessioned | 2024-08-14T01:02:00Z | - |
dc.date.available | 2024-08-14T01:02:00Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.issn | 2093-5951 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26515 | - |
dc.description.abstract | Background: Chronic rhinosinusitis (CRS) is further classified as CRS with nasal polyp and CRS without nasal polyp. It is also divided into type 2 and none-type 2 by immunological endotype. Nowadays, novel biological products targeting type 2 inflammation are developed and used for the treatment of CRS with nasal polyp.Current Concepts: Dupilumab, which inhibits interleukin-4 and interleukin-13, and omalizumab, which targets immunoglobulin E, were recently approved and are currently being used as the treatment regimen for patients with recurrent CRS with nasal polyp in Korea. Many studies demonstrated enough effects of both biological products on nasal symptoms, including smell, quality of life, and polyp size. The indication of biological products is refractory CRS with nasal polyp with severe symptoms even after endoscopic sinus surgery. However, the main drawback of these biological products is a high cost since they are non-reimbursement regimens as defined by Korean national health insurance.Discussion and Conclusion: Further research on the use of dupilumab and omalizumab in Korean patients will be needed because the Korean CRS endotype, which is characterized by less-type-2 CRS, is different from Western CRS endotypes. Additionally, investigations on the comparison of efficacy among various biological products are essential to prescribe the most appropriate biological products depending on the patients' endotypes. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN MEDICAL ASSOC | - |
dc.title | Treatment with biological products for chronic rhinosinusitis with nasal polyp | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5124/jkma.2023.66.9.532 | - |
dc.identifier.scopusid | 2-s2.0-85174534669 | - |
dc.identifier.wosid | 001075147200003 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, v.66, no.9, pp 532 - 536 | - |
dc.citation.title | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.volume | 66 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 532 | - |
dc.citation.endPage | 536 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002997292 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | OMALIZUMAB | - |
dc.subject.keywordAuthor | Rhinitis | - |
dc.subject.keywordAuthor | Sinusitis | - |
dc.subject.keywordAuthor | Nasal polyps | - |
dc.subject.keywordAuthor | Biological products | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.